Skip to main content
SpringerLink
Log in

Coronary no-reflow phenomenon

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Optional statement

No-reflow occurs in up to one third of patients with acute myocardial infarction during acute percutaneous intervention, and occasionally during elective interventions, particularly vein graft intervention. Multiple intracoronary medications will restore flow in most cases. We begin with 100 to 1000 μg of nitroprusside, verapamil, or adenosine at a similar dosage. We give it at 100-μg increments at high velocity. We inject it distally in the epicardial artery to avoid any systemic effect, and we do it through an intracoronary perfusion catheter. At times, we use prophylactic injections (prior to balloon inflation), particularly in vein graft intervention. Most of these strategies are not formally approved for treating no-reflow. However, reversing this condition with restoration of normal coronary flow is essential for an improved left ventricular function and a better cardiac outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rezkalla SH, Kloner RA: No-reflow phenomenon. Circulation 2002, 105:656–662. A comprehensive review about the disease history, pathophysiology, and treatment.

    Article  PubMed  Google Scholar 

  2. Kloner RA, Ganote CE, Jennings RB: The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974, 54:1496–1508.

    Article  PubMed  CAS  Google Scholar 

  3. Matetzky S, Novikov M, Gruberg L, et al.: The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999, 34:1932–1938.

    Article  PubMed  CAS  Google Scholar 

  4. Morishima I, Sone T, Mokuno S, et al.: Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995, 130:239–243.

    Article  PubMed  CAS  Google Scholar 

  5. Gibson CM, Murphy SA, Rizzo MJ, et al.: Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999, 99:1945–1950.

    PubMed  CAS  Google Scholar 

  6. Bolognese L, Antoniucci D, Rovai D, et al.: Myocardial contrast echocardiography versus dobutamine echocardiography for predicting functional recovery after acute myocardial infarction treated with primary coronary angioplasty. J Am Coll Cardiol 1996, 28:1677–1683.

    Article  PubMed  CAS  Google Scholar 

  7. Iwakura K, Ito H, Takiuchi S, et al.: Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation 1996, 94:1269–1275.

    PubMed  CAS  Google Scholar 

  8. Sherman JR, Anwar A, Bret JR, Schreibfeder MM: Distal vessel pullback angiography and pressure gradient measurement: an innovative diagnostic approach to evaluate the no-reflow phenomenon. Cathet Cardiovasc Diagn 1996, 39:1–6.

    Article  PubMed  CAS  Google Scholar 

  9. Iliceto S, Marangelli V, Marchese A, et al.: Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Eur Heart J 1996, 17:344–353.

    PubMed  CAS  Google Scholar 

  10. Kondo M, Nakano A, Saito D, Shimono Y: Assessment of “microvascular no-reflow phenomenon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998, 32:898–903.

    Article  PubMed  CAS  Google Scholar 

  11. Faraggi M, Karila-Cohen D, Brochet E, et al.: Relationship between resting 201Tl reverse redistribution, microvascular perfusion, and functional recovery in acute myocardial infarction. J Nucl Med 2000, 41:393–399.

    PubMed  CAS  Google Scholar 

  12. Bremerich J, Wendland MF, Arheden H, et al.: Microvascular injury in reperfused infarcted myocardium: noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging. J Am Coll Cardiol 1998, 32:787–793.

    Article  PubMed  CAS  Google Scholar 

  13. Wu KC, Zerhouni EA, Judd RM, et al.: Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998, 97:765–772.

    PubMed  CAS  Google Scholar 

  14. Kenner MD, Zajac EJ, Kondos GT, et al.: Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow-up. Am J Cardiol 1995, 76:861–868.

    Article  PubMed  CAS  Google Scholar 

  15. Morishima I, Sone T, Okumura K, et al.: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000, 36:1202–1209.

    Article  PubMed  CAS  Google Scholar 

  16. Iwakura K, Ito H, Ikushima M, et al.: Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003, 41:1–7.

    Article  PubMed  CAS  Google Scholar 

  17. Topol EJ, Yadav JS: Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000, 101:570–580.

    PubMed  CAS  Google Scholar 

  18. Silva JA, White CJ, Ramee SR, et al.: Treatment of coronary stent thrombosis with rheolytic thrombectomy: results from a multicenter experience. Catheter Cardiovasc Interv 2003, 58:11–17.

    Article  PubMed  Google Scholar 

  19. Baim DS, Wahr D, George B, et al.: Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002, 105:1285–1290.

    Article  PubMed  Google Scholar 

  20. Popma JJ, Cox N, Hauptmann KE, et al.: Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. Catheter Cardiovasc Interv 2002, 57:125–134.

    Article  PubMed  Google Scholar 

  21. Timurkaynak T, Ciftci H, Cengel A: Covered stent graft for primary PTCA of an aortocoronary vein graft. Acta Cardiol 2002, 57:305–308.

    Article  PubMed  Google Scholar 

  22. Sabatier R, Hamon M, Zhao QM, et al.: Could direct stenting reduce no-reflow in acute coronary syndromes? A randomized pilot study. Am Heart J 2002, 143:1027–1032.

    Article  PubMed  Google Scholar 

  23. Bowles M, Palko W, Beaver C, et al.: Clinical and postmortem outcome of “no-reflow” phenomenon in a patient treated with rotational atherectomy. South Med J 1996, 89:820–823.

    PubMed  CAS  Google Scholar 

  24. Giri S, Mitchel JF, Hirst JA, et al.: Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 2000, 86:269–274.

    Article  PubMed  CAS  Google Scholar 

  25. Tcheng JE, Kandzari DE, Grines CL, et al.: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003, 108:1316–1323.

    Article  PubMed  CAS  Google Scholar 

  26. Neumann FJ, Blasini R, Schmitt C, et al.: Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998, 98:2695–2701.

    PubMed  CAS  Google Scholar 

  27. Assali AR, Sdringola S, Ghani M, et al.: Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of “no reflow” phenomenon. Catheter Cardiovasc Interv 2000, 51:27–31; discussion 32.

    Article  PubMed  CAS  Google Scholar 

  28. Marzilli M, Orsini E, Marraccini P, Testa R: Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000, 101:2154–2159. Randomized study; adenosine versus placebo in the treatment of no-reflow.

    PubMed  CAS  Google Scholar 

  29. Fischell TA, Carter AJ, Foster MT, et al.: Reversal of “no reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998, 45:360–365.

    Article  PubMed  CAS  Google Scholar 

  30. Dillon WC, Hadian D, Ritchie ME: Refractory no-reflow successfully treated with local infusion of high-dose adenosine and verapamil—a case report. Angiology 2001, 52:137–141.

    PubMed  CAS  Google Scholar 

  31. Demir I, Yilmaz H, Ermis C, Sancaktar O: Treatment of no-reflow phenomenon with verapamil after primary stent deployment during myocardial infarction. Jpn Heart J 2002, 43:573–580.

    Article  PubMed  CAS  Google Scholar 

  32. Taniyama Y, Ito H, Iwakura K, et al.: Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997, 30:1193–1199.

    Article  PubMed  CAS  Google Scholar 

  33. Michaels AD, Appleby M, Otten MH, et al.: Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol 2002, 14:299–302.

    PubMed  Google Scholar 

  34. McIvor ME, Undemir C, Lawson J, Reddinger J: Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn 1995, 35:287–291; discussion 292–293.

    Article  PubMed  CAS  Google Scholar 

  35. Fugit MD, Rubal BJ, Donovan DJ: Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000, 12:80–85.

    PubMed  CAS  Google Scholar 

  36. Hillegass WB, Dean NA, Liao L, et al.: Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001, 37:1335–1343.

    Article  PubMed  CAS  Google Scholar 

  37. Ishihara M, Sato H, Tateishi H, et al.: Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996, 132:959–963.

    Article  PubMed  CAS  Google Scholar 

  38. Sakata Y, Kodama K, Ishikura F, et al.: Disappearance of the ’no-reflow’ phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997, 61:455–458.

    Article  PubMed  CAS  Google Scholar 

  39. Skelding KA, Goldstein JA, Mehta L, et al.: Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002, 57:305–309.

    Article  PubMed  Google Scholar 

  40. Baim DS: Epinephrine: a new pharmacologic treatment for no-reflow? Catheter Cardiovasc Interv 2002, 57:310–311.

    Article  PubMed  Google Scholar 

  41. Ito H, Taniyama Y, Iwakura K, et al.: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999, 33:654–660.

    Article  PubMed  CAS  Google Scholar 

  42. Amado LC, Kraitchman DL, Gerber BL, et al.: Reduction of “no-reflow” phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J Am Coll Cardiol 2004, 43:1291–1298.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Marshfield Clinic, 1000 North Oak Avenue, 54449, Marshfield, WI, USA

    Shereif H. Rezkalla MD

Authors
  1. Shereif H. Rezkalla MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Kloner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rezkalla, S.H., Kloner, R.A. Coronary no-reflow phenomenon. Curr Treat Options Cardio Med 7, 75–80 (2005). https://doi.org/10.1007/s11936-005-0008-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-005-0008-0

Keywords

Search

Navigation